Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,093 USD | +1.01% |
|
+3.67% | +24.42% |
07-12 | UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating | MT |
07-11 | Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.42% | 117B | |
+20.46% | 127B | |
+25.44% | 27.67B | |
-17.98% | 20.33B | |
-15.17% | 16.79B | |
-14.85% | 15.63B | |
+12.65% | 14.84B | |
-47.10% | 14.65B | |
+56.32% | 14.43B | |
+147.73% | 12.49B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 10